EUR 1.28
(5.79%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 62.63 Million USD | N/A |
2022 | 2.67 Million USD | 0.0% |
2021 | 1.09 Million USD | N/A |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 11.75 Million USD | 40.34% |
2024 Q1 | 8.37 Million USD | -22.61% |
2023 Q3 | 10.18 Million USD | -69.95% |
2023 Q4 | 10.82 Million USD | 6.28% |
2023 Q2 | 33.9 Million USD | 339.24% |
2023 Q1 | 7.71 Million USD | 0.0% |
2022 Q3 | 1.06 Million USD | 15.21% |
2022 FY | 27.16 Million USD | 0.0% |
2022 Q2 | 927 Thousand USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
BioNTech SE | 2.52 Billion EUR | 97.523% |
CureVac N.V. | 211.75 Million EUR | 70.419% |
Biotest Aktiengesellschaft | 136.8 Million EUR | 54.212% |
Biotest Aktiengesellschaft | 136.8 Million EUR | 54.212% |
BRAIN Biotech AG | 24.94 Million EUR | -151.145% |
Formycon AG | 23.73 Million EUR | -163.928% |
Heidelberg Pharma AG | 27.81 Million EUR | -125.188% |
Medigene AG | 20.54 Million EUR | -204.956% |